Superantigens - Powerful modifiers of the immune system

Molecular Medicine Today

Volumn 6, Issue 3, 2000, Pages 125-132

  Fraser, John ^a   Arcus, Vickery ^a   Kong, Philip ^a   Baker, Edward ^a   Proft, Thomas ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

SUPERANTIGEN; T LYMPHOCYTE RECEPTOR;

ANTIGEN BINDING; BACTERIAL INFECTION; HUMAN; IMMUNE SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; T LYMPHOCYTE ACTIVATION;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES;

EID: 0342751302     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(99)01657-3     Document Type: Review

References (51)

1. Marrack P., Kappler J. The Staphylococcal enterotoxins and their relatives. Science. 248:1990;705-711.
2. Kotzin B.L.et al. Superantigens and their potential role in human disease. Adv. Immunol. 54:1993;99-166.
3. Renno T., Acha-Orbea H. Superantigens in autoimmune diseases: still more shades of gray. Immunol. Rev. 154:1996;175-191.
4. Wannamaker L.W., Schlievert P.M. Exotoxins of group A Streptococci. Hardegree C.M., Tu A.T. Bacterial toxins (Vol. 4). 1988;267-295 Marcel Dekker.
5. Schlievert P.M. Role of superantigens in human disease. J. Inf. Dis. 167:1993;997-1002.
6. Hudson K.R.et al. Two adjacent residues in staphylococcal enterotoxins A and E determine T cell receptor Vβ specificity. J. Exp. Med. 177:1993;175-184.
7. Betley M.J., Mekalanos J.J. Nucleotide sequence of the type A staphylococcal enterotoxin gene. J Bacteriol. 170:1988;34-41.
8. Cole B.C., Atkin C.L. The Mycoplasma arthritidis T-cell mitogen, MAM: a model superantigen. Immunol. Today. 12:1991;271-276.
9. Hodtsev A.S.et al. Mycoplasma superantigen is a CDR3-dependent ligand for the T cell antigen receptor. J. Exp. Med. 187:1998;319-327.
10. Ito Y.et al. Sequence analysis of the gene for a novel superantigen produced by Yersinia pseudotuberculosis and expression of the recombinant protein. J. Immunol. 154:1995;5896-5906.
11. Schad E.M.et al. Crystal structure of the superantigen staphylococcal enterotoxin type A. Crystal structure of Staphylococcal enterotoxin B, a superantigen. EMBO J. 14:1995;3292-3301.
12. Swaminathan S.et al. Crystal structure of Staphylococcal enterotoxin B, a superantigen. Nature. 359:1992;801-806.
13. Papageorgiou A.C.et al. Crystal structure of the superantigen enterotoxin C2 from Staphylococcus aureus reveals a zinc-binding site. Structure. 3:1995;769-779.
14. 2+-mediated homodimerization. EMBO Journal. 15:1996;6832-6840.
15. Acharya K.R.et al. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Nature. 367:1994;94-97.
16. Roussel A.et al. Crystal structure of the streptococcal superantigen SPE-C: dimerization and zinc binding suggest a novel mode of interaction with MHC class II molecules. Nat. Struct. Biol. 4:1997;635-643.
17. Kim J., Urban R., Strominger J.L., Wiley D. Toxic Shock Syndrome Toxin-1 Complexed with a Major Histocompatibility Molecule HLA-DR1. Science. 266:1994;1870-1874.
18. Jardetzky T.S.et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature. 368:1994;711-718.
19. Fields B.A.et al. Crystal structure of a T-cell receptor β -chain complexed with a superantigen. Nature. 384:1996;188-192.
20. Li H.et al. Three-dimensional structure of the complex between a T-cell receptor β -chain and the superantigen staphylococcal enterotoxin B. Immunity. 9:1998;807-816.
21. Thibodeau J.et al. Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding. Science. 266:1994;1874-1878.
22. Mehindate K.et al. Cross-linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. J. Exp. Med. 182:1995;1573-1577.
23. Tiedemann R.E., Fraser J.D. Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T-cell activation. J. Immunol. 157:1996;3958-3966.
24. Proft T., Fraser J.D. Superantigens: just like peptides only different. J. Exp. Med. 187:1998;819-821.
25. Monks C.R.et al. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature. 395:1998;82-86.
26. Li P.L.et al. The superantigen streptococcal pyrogenic exotoxin C (SPE-C) exhibits a novel mode of action. J. Exp. Med. 186:1997;375-383.
27. Proft T.et al. Identification and characterization of novel superantigens from Streptococcus pyogenes. J. Exp. Med. 189:1999;89-102.
28. Leder L.et al. A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor β-chain and major histocompatibility class II. J. Exp. Med. 187:1998;823-833.
29. Valitutti S.et al. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature. 375:1995;148-151.
30. + T cells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature. 349:1991;245-248.
31. Bonfoco E.et al. Inducible non-lymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity. 9:1998;711-720.
32. Festenstein H., Kimura S. The Mls system: past and present. J. Immunogenet. 15:1988;183-196.
33. Acha-Orbea H., MacDonald H.R. Superantigens of mouse mammary tumor virus. Ann. Rev. Immunol. 13:1995;459-486.
34. Acha-Orbea H.et al. Mls: a link between immunology and retrovirology. Int. Rev. Immunol. 8:1992;327-336.
35. Grigg M.E.et al. Mtv-1 superantigen trafficks independently of major histocompatibility complex class II directly to the B-cell surface by the exocytic pathway. J. Virol. 72:1998;2577-2588.
36. Winslow G.M.et al. Detection and biochemical characterization of the mouse mammary tumor virus 7 superantigen (Mls-1a). Cell. 71:1992;719-730.
37. Dobrescu D.et al. Enhanced HIV-1 replication in Vβ 12 T cells due to human cytomegalovirus in monocytes: evidence for a putative herpesvirus superantigen. Cell. 82:1995;753-763.
38. Sutkowski N.et al. An Epstein-Barr virus-associated superantigen. J. Exp. Med. 184:1996;971-980.
39. Conrad B.et al. Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature. 371:1994;351-355.
40. Conrad B.et al. A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell. 90:1997;303-313.
41. Lower R.et al. Development of insulin-dependent diabetes mellitus does not depend on specific expression of the human endogenous retrovirus HERV-K. Cell. 95:1998;11-14.
42. Todd J., Tishant D. Toxic Shock syndrome associated with phage-group-1 Staphylococci. Lancet. 2:1978;1116-1118.
43. Choi Y.et al. Selective expansion of T cells expressing Vβ 2 in toxic shock syndrome. J. Exp. Med. 172:1990;981-984.
44. Abe J.et al. Characterization of T cell repertoire changes in acute Kawasaki disease. J. Exp. Med. 177:1993;791-796.
45. Leung D.Y.et al. The potential role of bacterial superantigens in the pathogenesis of Kawasaki syndrome. J. Clin. Immunol. 15:1995;11S-17S.
46. Paliard X.et al. Evidence for the effects of a superantigen in rheumatoid arthritis. Science. 253:1991;325-329.
47. Schiffenbauer J.et al. Staphylococcal enterotoxins can reactivate experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8543-8546.
48. Racke M.et al. Superantigen modulation of experimental allergic encephalomyelitis: activation of anergy determines outcome. J. Immunol. 152:1994;2051-2059.
49. Brocke S.et al. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature. 365:1993;642-644.
50. Thompson J.D.et al. The ClustalX windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 24:1997;4876-4882.
51. Konishi A case of Kawasaki's disease with coronary aneurysms documenting Yersinia pseudotuberculosis infection. Acta Paediatr. 86:1996;661-664.